• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 13, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Mutating Ebola’s key protein may stop replication

Bioengineer by Bioengineer
March 12, 2018
in Biology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

WEST LAFAYETTE, Ind. — Researchers may be able to stop the replication of Ebola virus by mutating its most important protein, according to a paper published in the Journal of Biological Chemistry.

Researchers were able to mutate Viral Protein 40 (VP40) in a way that changed the residues of the protein, blocking the budding and replication of Ebola virus in a model system.

VP40 is a peripheral membrane protein that regulates viral budding from the plasma membrane. It interacts with a human plasma-membrane lipid, phosphatidylserine, to facilitate replication of the virus. All animal viruses have to cross membranes for cell entry and exit.

The research team, led by Robert Stahelin of Purdue University, found the specific parts of VP40 that bind with the lipid: a cationic patch on the end of an amino acid chain. This site controls the ability of the protein to form a lipid envelope, the layer that protects the virus from the outside environment.

Water-attracting residues at this site are critical for membrane penetration and budding. Substituting those residues with alanine, which is hydrophobic, reduced lipid binding by 40-fold and stopped localization to the plasma membrane.

VP40 is a transformer protein, capable of rearranging itself into different structures: monomer, dimer and octamer. These various structures interact with the lipid differently, according to the paper. The dimer is best equipped to facilitate replication, performing twice as well as the monomer, and nearly 10 times better than the octamer.

"It's exciting to learn that these different oligomeric structures bind differently with the human lipid cells," Stahelin said. "That might explain why there are different roles for this protein in the viral replication cycle."

There are currently no FDA-approved vaccines or therapeutics available for Ebola virus. Outbreaks are rare but deadly, with fatality rates as high as 90 percent. Knowing how and where the protein interacts with the lipid could allow researchers to better target it with therapeutics.

"This helps us understand how the virus uses human cell membranes to replicate and form new virus particles. The virus needs this one lipid to form the new particle and infect other cells," Stahelin said. "We've been targeting human cells with therapeutics that modulate the way the cell makes lipids, and we like to target the human cell because it isn't likely to mutate and become resistant to the drug.

Cellular and in vitro models were used in this study. In vitro models were used to quantify how well VP40 binds to synthetic membranes. The researchers mutated the DNA code to change the amino acid sequence of VP40, purified those proteins to homogeneity and compared their bindings to that of the original VP40.

In cellular experiments, live cell imaging was used to monitor VP40 localization in human cells. The movement of the mutant VP40 and the original VP40 were compared to see how they bind to the human cell plasma membrane, the site of viral replication.

###

Stahelin collaborated with researchers from Florida International University, The Scripps Research Institute and the University of Notre Dame. The work was supported by National Institutes of Health (NIH) Grants AI081077 and AI121841, and NIH Health CBBI Predoctoral Training Fellowship T32GM075762.

Media Contact

Kayla Zacharias
[email protected]
765-494-9318
@PurdueUnivNews

http://www.purdue.edu/

http://www.purdue.edu/newsroom/releases/2018/Q1/mutating-ebolas-key-protein-may-stop-replication.html

Share12Tweet7Share2ShareShareShare1

Related Posts

Social Factors Impact Systemic Hormone Therapy Use in Midlife Women

Social Factors Impact Systemic Hormone Therapy Use in Midlife Women

October 12, 2025
Immunomodulatory Effects of Lacticaseibacillus casei Exopolysaccharides

Immunomodulatory Effects of Lacticaseibacillus casei Exopolysaccharides

October 12, 2025

Brainstem Connectivity Differences by Sex and Menopause

October 12, 2025

ERβ Provides Gender-Specific Defense Against Alzheimer’s Disease

October 12, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1227 shares
    Share 490 Tweet 306
  • New Study Reveals the Science Behind Exercise and Weight Loss

    103 shares
    Share 41 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    100 shares
    Share 40 Tweet 25
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    90 shares
    Share 36 Tweet 23

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary AI-Powered Service by Frontiers Transforms Data Sharing, Accelerating Scientific Breakthroughs Beyond the 90% Lost Barrier

AI-Powered Echocardiography Revolutionizes Cardiovascular Disease Care

Enhancing Social Skills in Preschoolers with Autism

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 64 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.